Point-of-Care Diagnostics Market Accelerates with Technological Advancements

Point-of-Care Diagnostics Market Size and Growth 2025 to 2034

The global point-of-care diagnostics market size accounted for USD 62.28 billion in 2024 and is predicted to reach around USD 82.78 billion by 2034, growing at a CAGR of 2.89% from 2025 to 2034.

Point-of-Care Diagnostics Market Key Takeaway

• In terms of revenue, the market is valued at $64.08 billion in 2025.
• It is projected to reach $82.78 billion by 2034.
• The market is expected to grow at a CAGR of 2.89% from 2025 to 2034.
• The North America region accounted for 42% of the total revenue share in 2024.
• By product, the infectious diseases segment accounted for the highest market share 61% in 2024. The glucose testing segment has captured the second position for revenue holders in 2024. 
• By end user, the clinics segment has captured a revenue share of around 38% in 2024.
• The home end-use segment is growing at a CAGR of 3.6% from 2025 to 2034.
• The Asia Pacific is the fastest-growing segment in the near future.

U.S. Point-of-Care Diagnostics Market Size and Growth 2025 to 2034

The U.S. point-of-care diagnostics market size was valued at USD 18.32 billion in 2024 and is expected to reach around USD 24.55 billion by 2034, growing at a CAGR of 3% from 2025 to 2034.

With the rising incidence and prevalence of lifestyle diseases in North America, the region is gaining traction. The greater awareness of self-testing and home care kits, as well as considerable adoption of novel technologies, are expected to boost the growth of the point of care diagnostics market in the North America.

On the other hand, the Asia-Pacific is estimated to be the most opportunistic segment during the forecast period. Due to the increasing number of market players exploring the region’s untapped economies, the Asia-Pacific market is expected to grow significantly over the forecast period. Furthermore, the increased use of point of care diagnostics kits in countries such as China, Japan, and India is a key driver of growth in the Asia-Pacific region.

Europe is expected to grow significantly in the point-of-care diagnostics market during the forecast period. Europe is experiencing a rise in the incidence rates of various diseases, along with the rise in adoption of new technologies. This increases the demand for the use of point-of-care diagnostics within the population. Thus, this promotes the market growth.

UK

The industries in the UK are utilizing various technological advancements in the development of new point-of-care diagnostics kits. At the same time, rising diseases are increasing their use. This increases their production, which in turn increase the collaboration among the industries.

Germany

There is a rise in the demand for the use of rapid point-of-care diagnostics approaches. Thus, new research is being conducted for their development to deal with the rising diseases. This is further supported by the government fundings.

What Factors Are Influencing the Asia Pacific Point-of-Care Testing Market?

The Asia Pacific Point-of-Care Testing Market is expected to witness significant growth over the forecast period, due to an increasing rate of chronic and infectious diseases in the region, as well as prolonged growth in the development of the healthcare infrastructure across Asia Pacific. Such tools will promote quicker diagnosis and treatment on the spot, which can dramatically improve patient outcomes and cut down healthcare expenditure. Such a dynamic setting renders Asia Pacific as one of the most attractive markets for point-of-care testing in the world.

The market of point-of-care diagnostics in China is growing quickly because the burden of chronic and infectious diseases is increasing. This country is projected to encounter the greatest epidemic of diabetes in the world, and there is a steady increase in the number of cases, thus resulting in the demand for quick and precise diagnostic tools. Other manifestations of diseases like malaria, schistosomiasis, tetanus, leishmaniasis, diarrhea, diphtheria, measles, tuberculosis, and a variety of sexually transmitted diseases are still fairly common, which is also an incentive to have an efficient POCT solution.

Point-of-Care Diagnostics Market Growth Factors

The medical devices utilized to get an instant result in the investigation (diagnosis & monitoring) of various diseases, such as cancer, diabetes, heart diseases, and others are referred to as point-of-care (POC) diagnostics in this report. The global point-of-care diagnostics industry has a lot of room for growth for both established and new companies. The point-of-care diagnostics market is growing due to technological developments in POC devices, rising infectious disease incidence, and increased expenditures by key companies.

The rising occurrences of target disorders, as well as the increased prevalence of infectious diseases such as tuberculosis and AIDS, are boosting the expansion of the point of care diagnostics industry. The growing desire for rapid tests among the general public is also helping the point-of-care diagnostics industry grow. The need to make the healthcare sector more patient-centered is proven to be a positive factor in the point-of-care diagnostics market’s growth rate. Many patients may find the centralized testing method inconvenient because of it necessitates multiple trips to clinics to complete the entire evaluation process. Point of care devices provides a much-needed boost in the direction of a patient-centric approach. As a result, the point-of-care diagnostics market may see a significant increase in growth rate during the forecast period.

Point-of-care diagnostics has changed patient care because of their simplicity and efficiency. POC technologies have evolved efficiency. Point-of-care diagnostics (POC) technologies have evolved and improved as the area of microfluidics has progressed. Microfabrication and microfluidics methods have advanced so much in the last several years that POC devices can now be made at a cheap cost, are simple to use, portable, and produce quick results. In the subject of microfluidics technology, there are numerous research projects underway.

Due to the usage of micro fluids, nano diagnostics, chips, point-of-care diagnostics is gaining widespread acceptability among patients throughout the world. The samples are taken from the patient’s site for completing tests, and findings can be obtained in a very short amount of time.

The increased frequency of chronic and infectious in developing economies is one of the primary factors driving the growth of point-of-care diagnostics market. The chronic diseases such as rheumatism, diabetes, and cancer are on the rise around the world for a variety of causes, including an ageing population, unhealthy lifestyle, and environmental factors.

The adoption of glucose monitoring testing kits is driven by factors such as the need for early detection of hyperglycemic and hypoglycemic diabetes, the high prevalence of diabetes, the convenience of continuous glucose monitoring over traditional monitoring, availability of glucose monitors, and increased awareness of the products around the world, and growing technological innovations.

Market Scope

Product Insights

Based on the product, the infectious diseases segment dominated the market with the highest share 61% in 2024. Due to the increased prevalence of various infectious disorders, the infectious diseases segment of the market is expected to grow significantly during the forecast period.

On the other hand, the glucose testing segment has captured the second position in 2023. The rising diabetic and cancer population, the adoption of new point-of-care diagnostics technologies, and the growing preference for home glucose testing are all factors that contribute to the growth of the glucose testing segment.

End User Insights

Based on the end user, hospital bedside led the market with highest share in 2024. Due to the rising prevalence of chronic diseases requiring long term care and frequent monitoring in critical care units, as well as rapidly growing awareness of the availability of cost-effective and highly innovative point of care diagnostics products, this segment accounted for the largest share of the point-of-care diagnostics market.

On the other hand, urgent care and retail clinic segment is expected to grow at a faster rate during the forecast period. The increase in the number of clinics and urgent care centers, as well as the government’s measures to improve patient care in hospitals through the use of quick point of care diagnostics tests and other programs, are expected to drive the expansion of this segment during the forecast period.

Key Companies & Market Share Insights

The various developmental strategies such as business expansion, investments, new product launches, acquisition, partnerships, joint venture, and mergers fosters market growth and offers lucrative growth opportunities to the market players. Precipio Inc., for example, joined the point of care diagnostics market in July 2020 by forming a partnership with ADS Biotech to create a COVID-19 detection test kit based on a lateral flow immunoassay.

Point-of-Care Diagnostics Market Comapnies

• Cardinal Health Inc.
• Trinity Biotech
• Bio-Rad Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Quidel Corporation
• Abbott Laboratories
• Mesa Biotech
• F. Hoffmann-La Roche Ltd
• Cepheid

Recent developments

• In October 2023, EKF Diagnostics opened its new state-of-the-art life sciences manufacturing facility in the U.S. This facility is designed to address the increasing demand of an expanding customer base.
  (Source: https://www.ekfdiagnostics.com)
• In February 2023, bioMérieux received U.S. FDA approval for its BIOFIRE SPOTFIRE respiratory panel system to expand its POC testing product range.
  (Source: https://www.biomerieux.com)
• In January 2023, Cipla announced the launch of Cippoint, a point-of-care testing device with testing of cardiac markers, diabetes, infectious diseases, thyroid function, inflammation, metabolic, and coagulation markers.
  (Source: https://drugscontrol.org)
• In May 2025, for the detection of Respiratory Syncytial Virus (RSV), SEKISUI Diagnostics, which is a global medical diagnostics manufacturer, has launched a new rapid diagnostic testing tool in professional healthcare settings, as per the recent announcements.
• In May 2025, a Medicare reimbursement coverage for its FebriDx test, which is a rapid point-of-care (POC) diagnostic used to distinguish between bacterial and non-bacterial acute respiratory infections, from US Medicare Administrative Contractor (MAC) to Lumos Diagnostics was recently confirmed.
• In May 2025, a collaboration between Neo Medical Inc, which is an innovator in handheld ultrasound technology, and the POCUS Certification Academy, a globally recognized provider of point-of-care ultrasound (POCUS) education and Inteleos which is non-profit organization, was announced. To educate, increase proficiency, and to enhance access to advanced diagnostic technology worldwide is the aim of this collaboration.

Segments Covered in the Report

By Product

• Blood Glucose Monitoring
• Infectious Diseases
• Cardiometabolic Diseases
• Pregnancy & Infertility Testing
• Hematology Testing
• Others

By End User

• Hospital Bedside
• Physician’s Office Lab
• Urgent Care & Retail Clinics
• Homecare/Self-testing

By Geography

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa